Tags

Type your tag names separated by a space and hit enter

[Atypical antipsychotic induced weight gain and metabolic disorders].
Rev Med Chil. 2009 Jan; 137(1):106-14.RM

Abstract

The advent of new antipsychotic drugs has improved the treatment of schizophrenic patients as well as those suffering from other severe psychiatric disorders. Its widespread use, however, has been associated to the development of obesity and metabolic disturbances such as diabetes mellitus, dyslipidemia and increased coronary risk. This has caused a serious concern, due to the high cardiovascular mortality that prematurely affects these patients. The etiology of these abnormalities is still a matter of debate, although it is generally believed that the new antipsychotic drugs have a control stimulating effect on appetite, and their use is associated to an increased level of cortisol and to an insulin-resistance state. In addition, there is an increase in inflammatory mediator and cytokine production, induced by the pathophysiology of the schizophrenic process itself and also caused by the direct action of the antipsychotic drugs. In spite of the mounting evidence, the metabolic management of these patients is still deficient. A close follow-up in the initial stages of the antipsychotic treatment is recommended, as well as giving advice about diet and physical exercise. Finally, when obesity or other conditions associated to metabolic syndrome appear, the recommendation is to switch to drugs with less secondary effects or to add adjuvant medications to improve the overall evolution of these patients.

Authors+Show Affiliations

Sección Endocrinología, Hospital Clínico de Universidad de Chile. projas@redclinicauchile.clNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

English Abstract
Journal Article
Research Support, Non-U.S. Gov't
Review

Language

spa

PubMed ID

19399331

Citation

Rojas G, Paula, et al. "[Atypical Antipsychotic Induced Weight Gain and Metabolic Disorders]." Revista Medica De Chile, vol. 137, no. 1, 2009, pp. 106-14.
Rojas G P, Poblete A C, Orellana G X, et al. [Atypical antipsychotic induced weight gain and metabolic disorders]. Rev Med Chil. 2009;137(1):106-14.
Rojas G, P., Poblete A, C., Orellana G, X., Rouliez A, K., & Liberman G, C. (2009). [Atypical antipsychotic induced weight gain and metabolic disorders]. Revista Medica De Chile, 137(1), 106-14. https://doi.org//S0034-98872009000100017
Rojas G P, et al. [Atypical Antipsychotic Induced Weight Gain and Metabolic Disorders]. Rev Med Chil. 2009;137(1):106-14. PubMed PMID: 19399331.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - [Atypical antipsychotic induced weight gain and metabolic disorders]. AU - Rojas G,Paula, AU - Poblete A,Catalina, AU - Orellana G,Ximena, AU - Rouliez A,Karen, AU - Liberman G,Claudio, Y1 - 2009/04/23/ PY - 2009/4/29/entrez PY - 2009/4/29/pubmed PY - 2009/11/18/medline SP - 106 EP - 14 JF - Revista medica de Chile JO - Rev Med Chil VL - 137 IS - 1 N2 - The advent of new antipsychotic drugs has improved the treatment of schizophrenic patients as well as those suffering from other severe psychiatric disorders. Its widespread use, however, has been associated to the development of obesity and metabolic disturbances such as diabetes mellitus, dyslipidemia and increased coronary risk. This has caused a serious concern, due to the high cardiovascular mortality that prematurely affects these patients. The etiology of these abnormalities is still a matter of debate, although it is generally believed that the new antipsychotic drugs have a control stimulating effect on appetite, and their use is associated to an increased level of cortisol and to an insulin-resistance state. In addition, there is an increase in inflammatory mediator and cytokine production, induced by the pathophysiology of the schizophrenic process itself and also caused by the direct action of the antipsychotic drugs. In spite of the mounting evidence, the metabolic management of these patients is still deficient. A close follow-up in the initial stages of the antipsychotic treatment is recommended, as well as giving advice about diet and physical exercise. Finally, when obesity or other conditions associated to metabolic syndrome appear, the recommendation is to switch to drugs with less secondary effects or to add adjuvant medications to improve the overall evolution of these patients. SN - 0034-9887 UR - https://www.unboundmedicine.com/medline/citation/19399331/[Atypical_antipsychotic_induced_weight_gain_and_metabolic_disorders]_ L2 - http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872009000100017&lng=en&nrm=iso&tlng=en DB - PRIME DP - Unbound Medicine ER -